Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US
Authors:
- 27 March 2016
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 174 (2) , 249-254
Abstract
Differences in regulatory actions between Japan, the European Union (EU) and the United States (US) regarding the approval date and primary endpoints of pivotal trials have never been analysed comprehensively. This study aimed to examine such differences in haematological malignancy indications not only in applications for new molecular entity agents but also in supplemental applications for additional indications. A total of 101 haematological malignancy indications were examined for 58 drugs. Only 30 indications were approved by the regulatory agencies of all three regions with 25, 9 and 67 indications being first approved in Japan, the EU and the US, respectively. Regarding the 18 indications approved only in the US, 13 were approved based on results of single-arm trials. The approval of all nine indications approved first in the EU was based on results of comparative trials. The primary endpoints were different between the EU and the US in 4 of 49 indications approved by both regulatory agencies, all of which were approved earlier in the US than in the EU. This analysis shows that the US Food and Drug Administration has taken the most active attitude to acceptance of surrogate endpoints in single-arm trials. Therefore, not only shorter review time but also this attitude may lead to earlier approval in US.Keywords
Funding Information
- JSPS KAKENHI (15K20967)
This publication has 17 references indexed in Scilit:
- Use of Multiple Endpoints and Approval Paths Depicts a Decade of FDA Oncology Drug ApprovalsClinical Cancer Research, 2013
- Decitabine in Older Adults With Acute Myeloid Leukemia: Why Was the Dream Broken?Journal of Clinical Oncology, 2013
- Gemtuzumab OzogamicinJournal of Clinical Oncology, 2013
- Boulevard of Broken Dreams: Drug Approval for Older Adults With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2012
- Rare Cancer Trial Design: Lessons from FDA ApprovalsClinical Cancer Research, 2012
- Pixantrone: a new agent for relapsed aggressive lymphomasThe Lancet Oncology, 2012
- Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory AgenciesNew England Journal of Medicine, 2012
- Evaluation of Oncology Drugs at the European Medicines Agency and US Food and Drug Administration: When Differences Have an Impact on Clinical PracticeJournal of Clinical Oncology, 2011
- Accelerated Approval of Oncology Products: The Food and Drug Administration ExperienceJNCI: Journal of the National Cancer Institute, 2011
- Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007JNCI: Journal of the National Cancer Institute, 2010